Want to see MYGN full AI Analyst Report?
Top Page
Myriad Genetics
(NASDAQ:MYGN)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.00
▼(-5.96% Downside)
Action:Reiterated
Date:08/30/26
The score is held down primarily by weak financial performance—persistent operating losses and still-negative free cash flow—despite strong gross margins and a serviceable balance sheet. Technicals add pressure as the stock trades below major moving averages with negative MACD. Valuation offers limited support because losses make the negative P/E less informative and there is no dividend yield provided.
Positive Factors
Strong Gross Margins
Sustained gross margins near 69–71% show that Myriad’s testing portfolio retains solid economics at the product level, providing a foundation for future operating leverage if the company can control costs and restore growth.
Negative Factors
Persistent Operating Losses
Large operating losses continue to overwhelm Myriad’s strong gross margins, showing that the current cost structure is not supported by revenue. Persistent losses weaken retained capital and make durable earnings improvement dependent on major operating changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margins
Sustained gross margins near 69–71% show that Myriad’s testing portfolio retains solid economics at the product level, providing a foundation for future operating leverage if the company can control costs and restore growth.
Read all positive factors
Myriad Genetics Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how revenue is split across the company’s business lines—clinical genetic testing, women's health and oncology tests, and any partner or pharmaceutical-related income. Reveals which products drive growth, where pricing or reimbursement risk is concentrated, and whether Myriad is diversifying away from dependence on a single offering.
Shows how revenue is split across the company’s business lines—clinical genetic testing, women's health and oncology tests, and any partner or pharmaceutical-related income. Reveals which products drive growth, where pricing or reimbursement risk is concentrated, and whether Myriad is diversifying away from dependence on a single offering.
Data provided by:
The Fly
The FlyMyriad Genetics (MYGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$308.95M
Dividend YieldN/A
Average Volume (3M)2.33M
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth-3.16%
EPS Growth72.02%
CountryUS
Employees2,700
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-1.19
Shares Outstanding95,649,640
10 Day Avg. Volume1,707,953
30 Day Avg. Volume2,328,555
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.56
Price to Sales (P/S)0.70
P/FCF Ratio-22.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.95Price Target Upside-7.52% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering7
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$778.09M
Myriad Genetics Business Overview & Revenue Model
Company Description
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer te...
How the Company Makes Money
Myriad Genetics makes money primarily by providing molecular diagnostic and genetic testing services and recognizing revenue when tests are performed and reported for patients. Its key revenue stream is testing revenue generated from ordering phys...
Myriad Genetics Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Positive
The call emphasized meaningful progress in core growth engines (double-digit hereditary cancer growth, robust GeneSight performance, solid gross margins and a deep product pipeline) and management reaffirmed full-year guidance and positive adjusted EBITDA expectations. Near-term pressures include a Q1 adjusted EBITDA loss, higher operating expense due to accelerated commercial hiring, and a notable prenatal revenue decline. Management is investing to drive back-half acceleration but execution (sales ramp, MRD adoption, payer reimbursement) will determine pace of recovery. On balance, the positives around market share gains, product launches and revenue guidance outweigh the short-term profitability and prenatal headwinds.Positive Updates
Revenue within Guidance
Q1 revenue of $200.4 million, up ~2% year-over-year and within the company's Q1 guidance range; management reaffirmed full-year revenue guidance of $860M–$880M.
Negative Updates
Q1 Profitability Shortfall and Cash Burn
Reported adjusted EBITDA loss (~$4.5M–$5M) and adjusted EPS loss of $0.09 in Q1; management noted Q1 is the heaviest cash burn quarter and that accelerated commercial investments contributed to the near-term loss.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue within Guidance
Q1 revenue of $200.4 million, up ~2% year-over-year and within the company's Q1 guidance range; management reaffirmed full-year revenue guidance of $860M–$880M.
Read all positive updates
Company Guidance
Management reaffirmed full‑year 2026 guidance of $860–$880 million revenue, adjusted gross margin of 68–69% and adjusted EBITDA of $37–$49 million, while expecting sequential revenue growth in the low single digits in Q2 that accelerates through the back half (H2 stronger than H1). Q1 results were revenue $200.4M (within guidance) with 385k test results, gross margin ~68.7–69%, an adjusted EBITDA loss of roughly $4.5–$5.0M and adjusted EPS loss of $0.09; average revenue per test improved ~2% YoY. Operational highlights underpinning the guide included Cancer Care Continuum revenue of $120.2M (+4% YoY) with hereditary testing volume +14% YoY (affected +10%, unaffected +16%), GeneSight revenue $38.3M (+24% YoY) on +7% volume and >39,000 ordering clinicians, prenatal revenue $41.9M (‑15% YoY) and Prolaris mid‑single‑digit growth. Management also cited $199M in available capital, a planned $35M investment in commercial capabilities, hiring of over 100 account executives, and timing for key launches (Prolaris+AI in June, FirstGene commercial in H2’26, broader Precise MRD expansion in Q3 and full MRD commercialization in Q1’27).Myriad Genetics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
54
Neutral
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 806.60M | 824.50M | 837.60M | 753.20M | 678.40M | 690.60M |
| Gross Profit | 555.20M | 576.60M | 585.40M | 517.00M | 476.40M | 493.00M |
| EBITDA | -45.20M | -330.90M | -59.50M | -197.40M | -84.70M | 12.30M |
| Net Income | -112.60M | -365.90M | -127.30M | -263.30M | -112.00M | -27.20M |
Balance Sheet | ||||||
| Total Assets | 638.90M | 706.60M | 1.03B | 1.15B | 1.20B | 1.32B |
| Cash, Cash Equivalents and Short-Term Investments | 115.20M | 149.60M | 102.40M | 140.90M | 114.90M | 338.80M |
| Total Debt | 210.50M | 209.80M | 140.30M | 152.10M | 145.00M | 92.30M |
| Total Liabilities | 335.00M | 338.60M | 326.50M | 363.30M | 312.90M | 352.90M |
| Stockholders Equity | 303.90M | 368.00M | 701.10M | 783.20M | 885.80M | 967.80M |
Cash Flow | ||||||
| Free Cash Flow | -8.60M | -25.60M | -38.40M | -184.20M | -151.60M | 600.00K |
| Operating Cash Flow | 7.70M | 1.80M | -8.70M | -110.90M | -106.30M | 18.60M |
| Investing Cash Flow | -21.90M | -27.40M | -11.90M | 31.90M | -77.50M | 274.40M |
| Financing Cash Flow | 47.20M | 64.20M | -7.40M | 152.90M | -8.00M | -150.60M |
Myriad Genetics Technical Analysis
Neutral
3.19
Price Trends
4.47
Negative
4.45
Negative
5.08
Negative
Market Momentum
-0.29
Negative
39.95
Neutral
71.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYGN, the sentiment is Neutral. The current price of 3.19 is above the 20-day moving average (MA) of 3.16, below the 50-day MA of 4.47, and below the 200-day MA of 5.08, indicating a neutral trend. The MACD of -0.29 indicates Negative momentum. The RSI at 39.95 is Neutral, neither overbought nor oversold. The STOCH value of 71.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MYGN.
Myriad Genetics Risk Analysis
Myriad Genetics disclosed 52 risk factors in its most recent earnings report. Myriad Genetics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Myriad Genetics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $2.57B | 23.17 | 32.81% | ― | 34.41% | 90.73% | |
71 Outperform | $1.02B | -49.51 | -4.15% | ― | 3.18% | -100.37% | |
60 Neutral | $2.24B | -8.80 | -6.31% | ― | 11.19% | 50.58% | |
54 Neutral | $1.79B | -15.44 | -46.47% | ― | -13.26% | 14.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $551.41M | -6.97 | -7.87% | ― | 6.83% | -69.59% | |
44 Neutral | $308.95M | -2.70 | -32.59% | ― | -3.16% | 72.02% |
* Healthcare Sector Average
MYGN
Myriad Genetics
3.23
-3.56
-52.43%
NEO
NeoGenomics
17.46
9.40
116.63%
CDNA
CareDx
49.86
36.76
280.61%
FLGT
Fulgent Genetics
19.65
-2.33
-10.60%
PSNL
Personalis
16.83
11.74
230.65%
CSTL
Castle Biosciences
32.65
9.56
41.40%
Myriad Genetics Corporate Events
Executive/Board Changes
Myriad Genetics Announces Resignation of Board Member Skovronsky
Neutral
Jun 23, 2026
On June 17, 2026, Myriad Genetics announced that board member Daniel M. Skovronsky, M.D., Ph.D., resigned from its Board of Directors with immediate effect. The company stated that his departure did not stem from any disagreement regarding its ope...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Myriad Genetics Holds 2026 Annual Meeting and Approves Plans
Positive
Jun 4, 2026
On June 4, 2026, Myriad Genetics held its Annual Meeting of stockholders, with approximately 82.33% of outstanding shares represented via webcast or proxy, and shareholders elected Paul M. Bisaro, Rashmi Kumar and Lee N. Newcomer, M.D. as Class II...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.